Nasdaq
$1.79▲ 2.78%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.9MShares out 1.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 10.1After-hours26.10.02 05:058-KKey event#●●●#●●●#●●●
Transcode Therapeutics, Inc.Bullish
TransCode Therapeutics reached an agreement with Yorkville to prepay $840,975, including $759,000 in principal, to waive amortization events through October 31, 2026. Following this payment, the remaining aggregate principal amount under the convertible notes is approximately $4.1 million.…more
$1.79+2.78%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.28Pre-market26.09.28 21:168-KKey event
Transcode Therapeutics, Inc.
TransCode Therapeutics announced updated Phase 1a clinical trial results for TTX-MC138, showing a 71.4% stable disease rate among 14 evaluable patients. The study met its primary endpoint, and no dose-limiting toxicities were reported up to the highest evaluated dose of 4.8 mg/kg, confirming a favorable safety profile.…more
$1.79+2.78%vs prev closeView filingShare - 9.21After-hours26.09.22 06:423Ownership
Transcode Therapeutics, Inc.
John A. Tattory, an officer of Transcode Therapeutics, has filed a limited power of attorney appointing Philippe P. Calais as his attorney-in-fact. This authorization grants the appointee the power to execute and file SEC forms, including Form 3, 4, 5, and Schedule 13D/13G, on behalf of the officer.…more
$1.79+2.78%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 21:12#●●●#●●●#●●●
TransCode Therapeutics to Present TTX-MC138 Phase 1a Data at ESMO 2026
TransCode Therapeutics will present the Phase 1a clinical evaluation results of TTX-MC138 for patients with advanced solid tumors at the ESMO 2026 Congress. This presentation highlights the initial clinical data for the drug candidate, warranting attention for future development progress.…more
$1.79+2.78%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.13Pre-market26.10.13 20:34
●●●●●●●● ●●●●● ●●●●●●
Natera and TransCode Therapeutics have entered a strategic collaboration to support patient enrollment for a Phase 2a clinical trial of TTX-MC138. The partnership will utilize Natera's Signatera test to identify eligible patients with molecular residual disease more efficiently.…more
$1.79+2.78%vs prev closeShareBenzinga - 9.28Pre-market26.09.28 21:11
●●●●●●●● ●●●●● ●●●●●●
TransCode Therapeutics announced that its Phase 1a trial for TTX-MC138 in advanced solid tumors met primary endpoints with demonstrated antitumor activity and safety. While the results show promising disease control, the company plans to continue clinical evaluation for further validation.…more
$1.79+2.78%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report